Latest Blog Posts Tagged "Academia/Nonprofit"
November 30, 2018
In 2017, MJFF convened leaders from academia and industry to form the Alpha-Synuclein Clinical Path Working Group to lay out a roadmap to advance drugs for this target.
November 16, 2018
Biopharmaceutical company AC Immune is testing its tool to show alpha-synuclein on brain scans, which could help diagnose and track Parkinson's and measure therapeutic impact.
October 23, 2018
The Phase II trial is recruiting people with PD ages 40 to 80 to test a drug that targets alpha-synuclein.
August 29, 2018
A study found people with Parkinson's had thinner retinas and those changes related to dopamine loss and physical symptoms.
July 17, 2018
A promising approach to stopping Parkinson's is to target the rogue protein alpha-synuclein. We share the latest on six trials testing therapies with this goal.
December 11, 2017
Dr. Dolhun discusses constipation, a common non-motor symptom in Parkinson's, and ways to treat it.
October 24, 2017
In a recent review paper, top Parkinson's experts outline unanswered questions hindering development of treatments against key protein alpha-synuclein.
July 10, 2017
Five projects targeting alpha-synuclein are in clinical trials with more preparing for testing.
June 29, 2017
MJFF scientist speaks to "Nature Reviews Drug Discovery" about alpha-synuclein research progress in Parkinson's disease.
June 22, 2017
MJFF-funded researchers published on a connection between the key Parkinson's protein alpha-synuclein and the immune system. This finding may point to a new way to stop or slow disease.